We have Vaccine for COVID-19! What to Recommend for Pregnant Women?

Quintana, Silvana Maria

doi:10.1055/s-0041-1726090

Cited by 8 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case report, the CoronaVac vaccine was administered to a pregnant woman and assumed to be safe according to the literature because inactivated vaccines consist of dead antigens and are safe for this specific group without any major adverse effects or damage to the fetus. Studies have revealed that the vaccination of pregnant women against influenza, hepatitis A, and tetanus, for example, is common practice 6 , 8 .…”

Section: Discussionmentioning

confidence: 99%

“…Clinical trials on their efficacy and safety did not include pregnant women; therefore, the decision to vaccinate pregnant women against COVID-19 is based on a risk-benefit ratio. In Brazil, pregnant healthcare professionals working on the frontline of the COVID-19 outbreak were immunized with CoronaVac® because this vaccine uses a known and safe technology for pregnancy as long as its use is recommended by a woman’s obstetrician 6 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report

Menegali

Schuelter‐Trevisol

Barbosa³

et al. 2021

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report

Menegali

Schuelter‐Trevisol

Barbosa³

et al. 2021

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

“…Thus, after several investigations, authorities determined that adenovirus vector vaccines could be used by pregnant women, and the TTS occurrence probability is similar to that in the general population (42). The decision about the better choice between the abovementioned vaccine platforms should be discussed between the health professional and the pregnant/ lactating woman, considering the effectiveness, security, and other parameters (43,44). Still, there are few published data on the COVID-19 vaccine in pregnant women, mainly because they are not usually included in vaccine clinical trials due to safety and responsibility concerns (45); nevertheless, several studies support its safety and effectiveness (46,47).…”

Section: Pregnant Covid-19 Vaccination: State Of the Artmentioning

confidence: 99%

Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has turned pregnant women’s healthcare into a worldwide public health challenge. Although initial data did not demonstrate pregnancy as a more susceptible period to severe outcomes of acute severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection, there are an increasing number of reports showing that not only pregnant women might be at significantly higher risk than non-pregnant women by COVID-19 but also the fetus. These findings may be related to adaptive changes that occur during pregnancy, such as the reduction in the residual respiratory capacity, the decrease in viral immune responses, and the increased risk for thromboembolic events. Additionally, despite the SARS-CoV-2 vertical transmission evidence being uncommon, maternal illness severity might reflect serious perinatal and neonatal outcomes. Thus, protecting the maternal–fetal dyad against COVID-19 is critical. Even though pregnant women initially were excluded from vaccine trials, several studies have provided safety and efficacy of the overall vaccine COVID-19 platforms. Vaccination during pregnancy becomes a priority and can generate benefits for both the mother and newborn: maternal neutralizing antibodies are transmitted through the placenta and breastfeeding. Moreover, regarding passive immunization, human milk contains other bioactive molecules and cells able to modulate the newborn’s immune response, which can be amplified after the vaccine. Nonetheless, many issues remain to be elucidated, considering the magnitude of the protective immunity transferred, the duration of the induced immunity, and the optimal interval for pregnant immunization. In this review, we assessed these unmet topics supported by literature evidence regarding the vaccine’s immunogenicity, pregnancy immune heterogeneity, and the unique human milk antiviral features.

show abstract

“…What to Recommend for Pregnant Women?" 1 Quintana 1 concluded that "The final decision whether or not to receive the vaccine will be made by the woman after receiving the appropriate information. This same principle applies with even greater emphasis to puerperal and lactating women."…”

Section: Dear Editormentioning

confidence: 99%